Mesenchymal-epithelial transition factor (MET), also known as c-Met or hepatocyte growth factor (HGF) receptor, is a receptor tyrosine kinase (RTK) that is overexpressed or mutated in various malignancies. MET and its associated signaling pathways are clinically important therapeutic targets. A number of small-molecule inhibitors and antibodies targeting MET and HGF are being developed as promising therapeutics for cancer, heart disease, autism, and other diseases. Sino Biological has developed a panel of c-MET proteins and HGF proteins from various species to help study the biology of MET signaling.